- Stocks
- Healthcare
- NASDAQ: EPZM

Price (delayed)

$10.19

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$1.1B

The gross profit has plunged by 55% YoY but it has grown by 27% from the previous quarter

The company's revenue rose by 35% QoQ but it fell by 34% YoY

EPZM's debt has soared by 163% from the previous quarter

The equity has contracted by 44% YoY and by 24% from the previous quarter

What are the main financial stats of EPZM

Market
Valuations
Earnings

Shares outstanding

101.79M

Market cap

$1.04B

Enterprise value

$1.1B

Price to earnings (P/E)

N/A

Price to book (P/B)

5.6

Price to sales (P/S)

65.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

70.09

Revenue

$15.76M

EBIT

-$226.9M

EBITDA

-$222.91M

Free cash flow

-$257.22M

Per share
Balance sheet
Liquidity

EPS

-$2.29

Free cash flow per share

-$2.55

Book value per share

$1.82

Revenue per share

$0.16

TBVPS

$4.23

Total assets

$473.57M

Total liabilities

$288.68M

Debt

$235.74M

Equity

$184.9M

Working capital

$361.69M

Debt to equity

1.28

Current ratio

9.33

Quick ratio

8.68

Net debt/EBITDA

-0.3

Margins
Efficiency
Dividend

EBITDA margin

-1,414.2%

Gross margin

67.9%

Net margin

-1,470%

Operating margin

-1,430.1%

Return on assets

-53.4%

Return on equity

-87.2%

Return on invested capital

-66.9%

Return on capital employed

-52.7%

Return on sales

-1,439.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Epizyme stock price performed over time

Intraday

-2.11%

1 week

-7.78%

1 month

-11%

1 year

-52.91%

YTD

-6.17%

QTD

-6.17%

How have Epizyme's revenue and profit performed over time

Revenue

$15.76M

Gross profit

$10.7M

Operating income

-$225.42M

Net income

-$231.69M

Gross margin

67.9%

Net margin

-1,470%

EPZM's net margin has plunged by 105% YoY but it is up by 23% from the previous quarter

Epizyme's operating margin has shrunk by 92% YoY but it has increased by 24% QoQ

The gross profit has plunged by 55% YoY but it has grown by 27% from the previous quarter

The net income has contracted by 36% YoY and by 4.4% from the previous quarter

What is Epizyme's growth rate over time

What is Epizyme stock price valuation

P/E

N/A

P/B

5.6

P/S

65.27

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

70.09

The EPS has decreased by 19% YoY and by 2.2% from the previous quarter

The equity has contracted by 44% YoY and by 24% from the previous quarter

The stock's P/B is 33% above its 5-year quarterly average of 4.2 and 6% above its last 4 quarters average of 5.3

EPZM's P/S is 36% below its 5-year quarterly average of 101.5 and 31% below its last 4 quarters average of 95.0

The company's revenue rose by 35% QoQ but it fell by 34% YoY

How efficient is Epizyme business performance

The ROS has plunged by 93% YoY but it has increased by 24% from the previous quarter

Epizyme's ROE has plunged by 69% YoY and by 19% from the previous quarter

The ROA has contracted by 21% YoY

EPZM's ROIC is up by 9% since the previous quarter

What is EPZM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EPZM.

How did Epizyme financials performed over time

The total assets is 64% more than the total liabilities

The total assets has grown by 24% from the previous quarter and by 12% YoY

The quick ratio has contracted by 22% YoY but it has grown by 6% from the previous quarter

EPZM's debt is 28% more than its equity

The equity has contracted by 44% YoY and by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.